OncoMatch/Clinical Trials/NCT07238075
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
Is NCT07238075 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ADCX-020 for advanced malignancy.
Treatment: ADCX-020 — The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors. ADCX-020 is an investigational anticancer therapy called antibody drug conjugate. This study is set up in multiple parts. In the first part of the study, participants receive increasing doses of ADCX-020. Then 2 or more doses will be assessed to identify the optimal dose. This optimal dose is subsequently evaluated for effect on different cancer types.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced/metastatic
Ph1a: Locally advanced or metastatic solid tumor relapsed or PD following local standard treatments, for which no standard treatment is available
Cannot have received: antibody-drug conjugate with topoisomerase 1 inhibitor payload
Phase 1b: Prior antibody drug conjugate exposure with a topoisomerase 1 inhibitor payload
Lab requirements
Cardiac function
Uncontrolled or significant cardiac disease including left ventricular ejection fraction (LVEF) <50%, myocardial infarction or uncontrolled/unstable angina
Uncontrolled or significant cardiac disease including left ventricular ejection fraction (LVEF) <50%, myocardial infarction or uncontrolled/unstable angina
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify